# Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

> **NCT04920747** · — · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 65 (actual)

## Conditions studied

- HER2-positive Gastric Cancer
- Metastatic Cancer
- Docetaxel
- Trastuzumab

## Interventions

- **DRUG:** Taxane

## Key facts

- **NCT ID:** NCT04920747
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920747, "Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04920747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*